Glucokinase activators in diabetes management
Authors:
- 30 January 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 17 (2) , 145-167
Abstract
Type 2 diabetes is a chronic metabolic disease that adversely affects both the quality and longevity of life. The disease is characterised by elevated blood glucose (hyperglycaemia) that is associated with microvascular complications and increased macrovascular risk. Existing oral agents, either alone or in combination, do not exhibit adequate or sustained glucose lowering efficacy in Type 2 diabetics. Consequently, there is an unmet medical need for improved antidiabetic agents which are both more effective at lowering glucose and which display sustained efficacy over a number of years. Such agents would allow present glycaemic treatment targets to be achieved with greater success. Glucokinase activators (GKAs) represent a novel class of glucose-lowering agents. Preclinical data supports the notion that these agents act to lower blood glucose through effects in both the liver and pancreas. It is predicted that this dual compartment mechanism of action of GKAs will translate to robust glucose lowering in ...Keywords
This publication has 106 references indexed in Scilit:
- Nature and causes of trends in male diabetes prevalence, undiagnosed diabetes, and the socioeconomic status health gradientProceedings of the National Academy of Sciences, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- A dominant role for glucose in β cell compensation of insulin resistanceJournal of Clinical Investigation, 2007
- Glucokinase and IRS-2 are required for compensatory cell hyperplasia in response to high-fat diet-induced insulin resistanceJournal of Clinical Investigation, 2007
- Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker ratsBritish Journal of Pharmacology, 2006
- Conformational transition pathway in the allosteric process of human glucokinaseProceedings of the National Academy of Sciences, 2006
- Enhancing hepatic glycolysis reduces obesity: Differential effects on lipogenesis depend on site of glycolytic modulationCell Metabolism, 2005
- Oral Antidiabetic AgentsDrugs, 2005
- Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemiaAmerican Heart Journal, 2004
- Observation of a kinetic slow transition in monomeric glucokinaseBiochemistry, 1990